Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST
| العنوان: | Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST |
|---|---|
| المؤلفون: | Bernard Higgins, Andrew Wilson, Rebecca Haydock, Mike Thomas, Charlotte Renwick, Graham Devereux, Lucy Bradshaw, David Price, Christopher E. Brightling, Samantha Walker, Kevin Mortimer, Lelia Duley, Tricia M. McKeever, Ian D. Pavord, Steve Parrott, Tim Harrison, Eleanor J Mitchell |
| المصدر: | Health Technology Assessment, Vol 22, Iss 70 (2018) |
| بيانات النشر: | National Institute for Health Research, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, lcsh:Medical technology, Technology Assessment, Biomedical, Exacerbation, Cost-Benefit Analysis, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Quality of life, Adrenal Cortex Hormones, law, medicine, Humans, Anti-Asthmatic Agents, 030212 general & internal medicine, Adverse effect, Asthma, Dose-Response Relationship, Drug, business.industry, Self-Management, Health Policy, Hazard ratio, Middle Aged, medicine.disease, United Kingdom, Confidence interval, Clinical trial, lcsh:R855-855.5, 030228 respiratory system, Emergency medicine, Quality of Life, Female, business, Research Article |
| الوصف: | BackgroundAsthma exacerbations affect the quality of life of patients with asthma and have a major effect on the overall costs of asthma care. An asthma self-management plan that advises the temporary quadrupling of inhaled corticosteroid dose may prevent asthma exacerbations, but this needs to be confirmed before being adopted widely.ObjectivesTo compare the clinical effectiveness and cost-effectiveness of an asthma self-management plan that advises patients to temporarily quadruple the dose of inhaled corticosteroid when asthma control starts to deteriorate with a standard self-management plan.DesignA multicentre, parallel-group, pragmatic randomised trial, with follow-up for 12 months.SettingPrimary and secondary care across 207 sites in the UK.ParticipantsAsthma patients aged ≥ 16 years treated with an inhaled corticosteroid who had experienced at least one exacerbation in the previous 12 months.InterventionsParticipants were randomised (1 : 1) to a usual-care self-management plan or to a modified self-management plan that advised a temporary quadrupling of the inhaled corticosteroid at the point of asthma deterioration, both of which were actively implemented and supported by local research staff.Primary outcomeThe primary outcome of ‘time to first asthma exacerbation’ was defined as the need for systemic corticosteroids (for at least 3 consecutive days) and/or unscheduled health-care consultations for asthma (i.e. reaching zone 3 or 4 of the Asthma UK self-management plan).ResultsA total of 1922 participants were randomised: the primary analysis included 938 participants (97%) in the usual-care group and 933 participants (97%) in the modified self-management group. The number of participants having at least one exacerbation of asthma in the year after randomisation was 484 (51.6%) in the usual-care group and 420 (45.0%) in the modified self-management group [adjusted hazard ratio 0.81, 95% confidence interval (CI) 0.71 to 0.92;p = 0.002]. There were fewer serious adverse events reported in the modified self-management group than in the usual-care group (11 vs. 32, respectively). Eight and six events of pneumonia, lower respiratory tract infections or influenza were reported in the usual-care group and the modified self-management group, respectively. Health-care-related costs were lower in the modified self-management group. The modified self-management group was £24 (bootstrapped 95% CI –£122 to £71) less costly than usual care, with a greater quality-adjusted life-year gain of 0.02 (bootstrapped 95% CI –0.005 to 0.04). Therefore, the modified self-management group was ‘dominant’, with a 94–95% probability of being cost-effective at the £20,000–30,000 threshold.LimitationsAs the Fourfold Asthma STudy (FAST) was an open-label pragmatic trial, the possibility of treatment bias that may have affected the participants in the modified self-management group cannot be ruled out. Poorer than expected completion of participant diary cards, particularly within the usual-care self-management group, could have led to a null bias, underestimating the true effect of the intervention.ConclusionsAn asthma self-management plan that advises patients to temporarily quadruple their dose of inhaled corticosteroid at the point of asthma symptoms worsening does reduce clinically important asthma exacerbations. In addition, the plan is cost-effective compared with the usual-care self-management plan.Future workTo effectively implement asthma self-management plans that advise a temporary quadrupling of inhaled steroid at asthma deterioration into routine practice.Trial registrationCurrent Controlled Trials ISRCTN15441965.FundingThis project was funded by the NIHR Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 22, No. 70. See the NIHR Journals Library website for further project information. |
| تدمد: | 2046-4924 1366-5278 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::996ef216db00397617165664090fcb68Test https://doi.org/10.3310/hta22700Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....996ef216db00397617165664090fcb68 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20464924 13665278 |
|---|